BAM15 vs Tirzepatide
A side-by-side research comparison of BAM15 and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BAM15 | Tirzepatide |
|---|---|---|
| Full name | BAM15 (Mitochondrial Uncoupler) | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | FDA Approved |
| Mechanism | Selectively transports protons across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than ATP. Cells burn more substrate (fat and glucose) to maintain energy, increasing metabolic rate without stimulating the CNS. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 402.28 Da | 4,814 Da |
| Half-life | Short (hours in animal models) | 5 days (120 hours) |
| Bioavailability | Oral (animal studies) | High (SubQ ~80%) |
| Typical dose | Not established for humans | 2.5 mg → titrate up to 15 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Oral (research) | Subcutaneous injection |
BAM15 reported benefits
- Increases metabolic rate/energy expenditure
- Fat loss without appetite suppression
- Improved insulin sensitivity (animal models)
- Reduced liver fat
- Wider safety margin than DNP (preclinical)
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.